HNSN Hansen Medical, Inc. (MM)

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced it has named veteran medical device sales executive Michael T. MacKinnon Vice President U.S. Commercial Operations. MacKinnon will report directly to President and Chief Executive Officer Bruce J Barclay.

MacKinnon has more than 17 years of sales experience for a variety of medical device companies in the vascular market, and other high-tech companies, including small start-ups and large public companies. Throughout his career he has built, trained and managed sales forces and worked closely and successfully with large corporate clients.

"Mike has had an outstanding career in sales. His demonstrated success in developing a national sales organization, and delivering significant growth of new medical device products in the large and growing vascular market, is a natural fit for Hansen Medical at this time," Barclay said. "His experience includes the ability to grow sales with new products that involve a training component, which will be very important as we take our next generation flexible robotics technology to the larger vascular market. He understands the value of clinical data and training to the successful sales of medical devices. Mike has substantial experience in working with Endovascular Surgeons, and Interventional Cardiologists and Radiologists, in the strategically important lower extremity Peripheral Vascular Disease (PVD) market, and experience in selling capital equipment. Mike is a high energy, relentless leader whose addition to our management team positions us well for success going forward."

"I am excited to be joining Hansen Medical at this pivotal time in the Company's history to help take it to the next stage of growth," said MacKinnon. "Hansen Medical is gaining momentum in key areas of its business, and I believe that the Company's flexible robotics technology has the potential to demonstrate the clinical and economic value increasingly demanded by physicians and payers alike through benefits such as reduced procedure time and reduced exposure to fluoroscopy for both patients and physicians, and greater access to hard-to-reach anatomy leading to fewer open surgeries. My priorities coming into the Company will be to work with the U.S. sales team to help drive improved results, and to prepare for the successful launch of the vascular robotic system in 2011."

Prior to coming to Hansen Medical, MacKinnon spent more than four years as Vice President of U.S. Sales at AccessClosure, Inc., a privately-held medical device company that develops products designed to address vascular closure during interventional and diagnostic procedures. At AccessClosure, MacKinnon built the U.S. sales organization from inception, which resulted in sales growth from product launch in 2007 to over $70 million per year in 2010 in the U.S. From 2004 to 2006, MacKinnon was a sales executive and later director of U.S. sales for FoxHollow Technologies, Inc., a public medical device company focused on the sale of plaque excision atherectomy devices for the treatment of PVD. Sales at FoxHollow grew to approximately $200 million annually worldwide, leading to its acquisition by ev3, Inc. in 2007 for $780 million.

MacKinnon has a Bachelor of Science degree in Business Administration from the University of Massachusetts.

About Hansen Medical, Inc. Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company's Sensei® system and its Sensei X Robotic Catheter System were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established during EP procedures, such as guiding catheters in the treatment of AF. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF, and the Lynx™ robotic catheter is cleared for AF ablation. The Company's investigational flexible catheter vascular robotic system requires regulatory filings and approval and is not commercially available. Additional information can be found at www.hansenmedical.com.

Forward-Looking Statements This press release contains forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hansen's results to differ materially from those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "potential," "plan" and similar words. Hansen Medical intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include the statement about the potential of flexible robotics to demonstrate clinical and economic value. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, potential safety and regulatory issues that could delay, suspend or terminate clinical studies, regulatory approvals or sales, challenges in designing, engineering and manufacturing systems to function as intended, uncertain timelines, costs and results of clinical trials and development of new products, our ability to plan and manage cost-reduction or operational efficiency initiatives, the scope and validity of intellectual property rights applicable to products being developed, and our ability to remediate material weaknesses in internal controls over financial reporting. These and other risks are described in greater detail under the heading "Risk Factors" contained in our periodic SEC filings, including our Quarterly Report on Form 10-Q filed with the SEC on November 9, 2010. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Hansen Medical, Heart Design, Hansen Medical & Heart Design, and Sensei are registered trademarks, and Lynx is a trademark, of Hansen Medical, Inc. in the United States and other countries.

Investor Contacts: Peter Osborne Interim CFO Hansen Medical 650.404.5800 Matt Clawson Allen & Caron Inc 949.474.4300 Email Contact